Nuvig Therapeutics Names David Woodhouse CEO, James Mackay Board Chair
Nuvig Therapeutics Strengthens Leadership Team with Appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair Nuvig Therapeutics, Inc. (“Nuvig”), a privately…
RION Launches INTENT Biologics, Names Suneet Varma CEO
RION Launches INTENT Biologics to Advance Late-Stage Clinical Exosome Therapies in Inflammation & Immunology; Appoints Industry Leader Suneet Varma as CEO RION, a clinical-stage regenerative medicine company recognized globally for…
Evonik Partners with Ethris to Advance Nucleic Acid Delivery Solutions
Evonik and Ethris Forge Strategic Alliance to Redefine Nucleic Acid Delivery with Novel Lipid Nanoparticle Platform In a move that underscores the rapid evolution of nucleic acid-based medicines and the…
CyPath® Lung Detects Cancer in Challenging Pulmonary Nodules
CyPath® Lung Demonstrates Diagnostic Power in Detecting Cancer Within Ground-Glass Nodules: A Case Study Highlighting bioAffinity Technologies’ Advancements in Noninvasive Lung Cancer Detection Lung cancer remains one of the deadliest…
Corner Therapeutics Unveils Breakthrough Flu Vaccine Approach with Oncology Potential
Corner Therapeutics Research Opens Door to Universal Flu Vaccine and Expands Promise for Cancer Immunotherapy Corner Therapeutics, a biotechnology company specializing in in vivo T cell modulation and immunotherapy, has…
Alnylam to Launch $500 Million Convertible Senior Notes Offering
Alnylam Pharmaceuticals Launches $500 Million Convertible Senior Notes Offering to Strengthen Strategic Flexibility and Advance RNAi Pipeline Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the biotechnology pioneer recognized worldwide as the leader…
JCR Pharma Shares Long-Term Data on Pabinafusp Alfa in MPS II at ICIEM 2025
JCR Pharmaceuticals Showcases Landmark Five-Year Clinical Data on Pabinafusp Alfa at ICIEM 2025, Reinforcing Transformative Potential for Patients with Hunter Syndrome and Expanding Pipeline of Brain-Penetrant Enzyme Replacement Therapies In…
Cellworks Launches Breakthrough Platform to Predict Chemo-Immunotherapy Response in Metastatic NSCLC
Cellworks Unveils Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLC Cellworks Group Inc., a leader in personalized therapy decision support and best-in-class patient-specific treatment response simulations (PTRS), has…
Tolerance Bio, ZipCode Bio Partner on Thymus Therapeutics
Tolerance Bio and ZipCode Bio Forge Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics In a landmark move that underscores the growing intersection of immunology and RNA-based medicine, Tolerance Bio,…
GE HealthCare to Distribute Flyrcado via CDL Nuclear Technologies
GE HealthCare and CDL Nuclear Technologies Partner to Expand Access to Flyrcado™, a Novel Cardiac PET Imaging Agent, Across the United States GE HealthCare (Nasdaq: GEHC) has announced a pivotal…
Amazon Pharmacy Launches $5 RxPass Subscription in Texas
Amazon Pharmacy Expands $5 RxPass Subscription Service to Texas, Offering Affordable Medication Access for Millions Amazon Pharmacy, the digital healthcare arm of Amazon, announced today that it is expanding RxPass,…
FDA Expands Approval of VONVENDI for Von Willebrand Disease in Adults and Children
FDA Expands Approval of Takeda’s VONVENDI®, First Recombinant von Willebrand Factor Therapy, to Include Routine Prophylaxis for Adults and Children with von Willebrand Disease Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), a…